Abstract
Platinum-based anticancer chemotherapy is associated to severe side effects because of its poor specificity. In particular, the hydrolysis of Pt-based drugs generates cationic complexes with electrophylic properties able to target DNA. The effectiveness of this kind of chemotherapy relies solely on the proliferation index of tumour cells, which is higher than in healthy cells. In recent years, the “drug targeting and delivery” approach has been developed in an attempt to reduce chemotherapy-related systemic side effects by using vectors that selectively deliver the cytotoxic agent to tumour cells, thus sparing healthy cells. These vectors include bioactive substances, such as nutrients, that more readily enter metabolically active tumour cells, or hormones, folates and bile acids, that are selectively conveyed by receptors/transporters often over-expressed in cancer cells (active targeting). Alternatively, macromolecular vectors, exploiting the so-called EPR (enhanced permeability and retention) effect, can be used (passive targeting). The bioactive or macromolecular vector must contain a coordinating arm capable of binding the PtX2-unit, acting either as carrier or leaving group for the cytotoxic Pt-moiety. In both cases, the Pt-vector conjugate should be promptly cleaved to generate the active species. The release of platinum drugs from the pharmacophore is crucial for fine-tuning of the overall cytotoxic properties of the conjugates. The “drug targeting and delivery” method represents an exciting field of research for improving the therapeutic potential of the long established, very efficient, but intrinsically non-specific Pt-based drugs.
Keywords: Anticancer Pt-based drugs, drug targeting and delivery, EPR effect
Current Medicinal Chemistry
Title: The Drug Targeting and Delivery Approach Applied to Pt-Antitumour Complexes. A Coordination Point of View
Volume: 16 Issue: 34
Author(s): E. Gabano, M. Ravera and D. Osella
Affiliation:
Keywords: Anticancer Pt-based drugs, drug targeting and delivery, EPR effect
Abstract: Platinum-based anticancer chemotherapy is associated to severe side effects because of its poor specificity. In particular, the hydrolysis of Pt-based drugs generates cationic complexes with electrophylic properties able to target DNA. The effectiveness of this kind of chemotherapy relies solely on the proliferation index of tumour cells, which is higher than in healthy cells. In recent years, the “drug targeting and delivery” approach has been developed in an attempt to reduce chemotherapy-related systemic side effects by using vectors that selectively deliver the cytotoxic agent to tumour cells, thus sparing healthy cells. These vectors include bioactive substances, such as nutrients, that more readily enter metabolically active tumour cells, or hormones, folates and bile acids, that are selectively conveyed by receptors/transporters often over-expressed in cancer cells (active targeting). Alternatively, macromolecular vectors, exploiting the so-called EPR (enhanced permeability and retention) effect, can be used (passive targeting). The bioactive or macromolecular vector must contain a coordinating arm capable of binding the PtX2-unit, acting either as carrier or leaving group for the cytotoxic Pt-moiety. In both cases, the Pt-vector conjugate should be promptly cleaved to generate the active species. The release of platinum drugs from the pharmacophore is crucial for fine-tuning of the overall cytotoxic properties of the conjugates. The “drug targeting and delivery” method represents an exciting field of research for improving the therapeutic potential of the long established, very efficient, but intrinsically non-specific Pt-based drugs.
Export Options
About this article
Cite this article as:
Gabano E., Ravera M. and Osella D., The Drug Targeting and Delivery Approach Applied to Pt-Antitumour Complexes. A Coordination Point of View, Current Medicinal Chemistry 2009; 16 (34) . https://dx.doi.org/10.2174/092986709789760661
DOI https://dx.doi.org/10.2174/092986709789760661 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Strategies for Preparing Different Types of Lipid Polymer Hybrid Nanoparticles in Targeted Tumor Therapy
Current Pharmaceutical Design Radiolabelled Peptides and Monoclonal Antibodies for Therapy Decision Making in Inflammatory Diseases
Current Pharmaceutical Design Extra-Hepatic Isozymes from the CYP1 and CYP2 Families as Potential Chemotherapeutic Targets
Current Topics in Medicinal Chemistry Translational Optical Imaging in Diagnosis and Treatment of Cancer
Current Pharmaceutical Biotechnology Oncogene-Blocking Therapies: New Insights from Conditional Mouse Tumor Models
Current Cancer Drug Targets Are Bacteriocins Underexploited? NOVEL Applications for OLD Antimicrobials
Current Pharmaceutical Biotechnology Butyrate and Colorectal Cancer: The Role of Butyrate Transport
Current Drug Metabolism Exosomes: A Promising Factor Involved in Cancer Hypoxic Microenvironments
Current Medicinal Chemistry Using Cytokines to Treat Cervical Intraepithelial and Invasive Neoplasia
Recent Patents on Anti-Cancer Drug Discovery An Investigative Approach to Treatment Modalities for Squamous Cell Carcinoma of Skin
Current Drug Delivery Pomegranate Extract, A Prooxidant with Antiproliferative and Proapoptotic Activities Preferentially Towards Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Acid-extrusion from Tissue: The Interplay Between Membrane Transporters and pH Buffers
Current Pharmaceutical Design The Role of Hesperidin in Cell Signal Transduction Pathway for the Prevention or Treatment of Cancer
Current Medicinal Chemistry Current Targeting Strategies for Adenovirus Vectors in Cancer Gene Therapy
Current Cancer Drug Targets Surgical Management of Medullary Thyroid Carcinoma in Pediatric Age
Current Pediatric Reviews Fluorescence Imaging in Cancerology
Current Molecular Imaging (Discontinued) The Clinical Prognostic Value of LRG1 in Esophageal Squamous Cell Carcinoma
Current Cancer Drug Targets The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
Current Medicinal Chemistry Analysis of miRNAs Targeting 3’UTR of H2AFX Gene: a General <i>in Silico</i> Approach
MicroRNA Anti-Cancer Activities of Tea Epigallocatechin-3-Gallate in Breast Cancer Patients under Radiotherapy
Current Molecular Medicine